Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases.
It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases.
The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation.
It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.
The company was incorporated in 2009 and is based in Norwood, Massachusetts.
500 River Ridge Drive
Norwood, Massachusetts 02062
|Phone||617 963 0100|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Dr. Yuval Cohen Ph.D.||Chief Executive Officer and Director|
|Sean F. Moran CPA, M.B.A., CPA, MBA||Chief Financial Officer|
|Craig Stuart Millian M.B.A.||Chief Operating Officer|
|Dr. Rachael Brake Ph.D.||Chief Scientific Officer|
|Ted Jenkins||Senior Director of Investor Relations and Corporate Communications|
|Lindsey Smith||Head of Corporate Communications and Patient Advocacy|
|Christina Bertsch||Head of Human Resources|
|Scott Constantine||Senior Director and Head of Clinical Operations|
Latest SEC Filings
|Aug 9, 2022||10-Q||Quarterly Report|
|Aug 9, 2022||8-K||Current Report|
|Jul 7, 2022||8-K||Current Report|
|Jun 8, 2022||8-K||Current Report|
|May 23, 2022||8-K||Current Report|
|May 17, 2022||8-K||Current Report|
|May 10, 2022||10-Q||Quarterly Report|
|May 10, 2022||8-K||Current Report|
|Apr 15, 2022||8-K||Current Report|
|Apr 11, 2022||8-K||Current Report|